SSAT AS A DETERMINANT OF DRUG ACTION
SSAT 作为药物作用的决定因素
基本信息
- 批准号:2896271
- 负责人:
- 金额:$ 28.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-08-01 至 2002-07-31
- 项目状态:已结题
- 来源:
- 关键词:acyltransferase antineoplastics carcinogenesis cell line cytotoxicity disease /disorder model enzyme activity enzyme induction /repression gene expression gene targeting genetic translation genetically modified animals homeostasis laboratory mouse melanoma messenger RNA neoplastic cell pharmacokinetics phorbols protein kinase C spermidine spermine
项目摘要
DESCRIPTION: Induction of the polyamine catabolic enzyme
spermidine/spermine N1-acetyltransferase (SSAT) by certain polyamine analogs
represents one of the most potent known gene responses attributable to an
anticancer drug. The relationship of this response to antitumor activity
and host toxicities has not yet been clearly established. The proposed
studies build on the following observations and developments involving this
novel enzyme: a) a polyamine analog currently undergoing phase 1 clinical
trial (N1, N11 -diethyl-norspermine (DENSPM) is an extremely potent inducer
of this enzyme; b) melanoma cells are more responsive to SSAT induction than
most other tumor cell types; c) biological correlations suggest a causal
linkage between analog induction of SSAT activity and in vitro and in vivo
growth sensitivity of tumor cells; d) overexpression of the enzyme in
transgenic animals causes striking phenotypic changes involving skin and the
female reproductive tract; e) strong similarities between SSAT transgenic
animals and certain other transgenics suggest a role for the enzyme in tumor
promotion and f) SSAT gene expression in mouse skin and melanoma cells is
markedly increased by 12-O-tetradecanoyl-13-phorbol acetate (TPA). The
Specific Aims propose: 1) to examine the cellular consequences of SSAT
induction in human melanoma cells transfected with a tetracycline-inducible
SSAT expression system; 2) to investigate the significance of translational
control of SSAT gene expression; 3) to examine the physiological role of
SSAT in tissue function using activated gene knock-out (via subcontract
agreement with Dr. J. Janne's group Kuopio, Finland); 4) to utilize systems
developed in aims 1-3 to study the role of SSAT in determining antitumor and
toxicity responses to clinically relevant polyamine antagonists; 5) to
determine via cross-breeding experiments whether SSAT overexpression renders
animals more or less prone to skin carcinogenesis and 6) as a mechanistic
correlate to aim 5, they propose to examine the effects of tumor promters on
SSAT gene expression and the possible role of protein kinase C as a mediator
of SSAT induction by both TPA and the polyamine analogs. In addition to
investigating the biological significance of this unusual enzyme response,
the proposed studies are designed to provide therapeutic insights and
preclinical model systems for use in facilitating the ongoing clinical and
preclinical development of experimental anticancer therapies targeting
polyamines.
描述:多胺分解代谢酶的诱导
某些多胺类似物对亚精胺/精胺N1-乙酰转移酶(SSAT)的影响
代表了已知的最有效的基因反应之一,可归因于
抗癌药物。这种反应与抗肿瘤活性的关系
寄主毒性尚未明确确定。建议数
研究建立在以下观察和涉及到的发展的基础上
新酶:a)一种多胺类似物,目前正处于临床1期
试验(N1,N11-二乙基去甲精胺(DENSPM)是一种非常有效的诱导剂
B)黑色素瘤细胞对SSAT诱导的反应比
大多数其他类型的肿瘤细胞;c)生物相关性提示原因
模拟诱导SSAT活性与体内外的联系
肿瘤细胞的生长敏感性;d)该酶在
转基因动物引起显著的表型变化,涉及皮肤和
女性生殖道;e)SSAT转基因基因之间有很强的相似性
动物和其他转基因研究表明,这种酶在肿瘤中发挥了作用
SSAT基因在小鼠皮肤和黑色素瘤细胞中的表达
12-O-十四酰-13-佛波醇醋酸酯(TPA)显著增加。这个
具体目标建议:1)检查SSAT的细胞后果
四环素诱导物对人黑色素瘤细胞的诱导作用
SSAT表达系统;2)研究翻译的意义
SSAT基因表达的调控;3)检测SSAT的生理作用
利用激活基因敲除的组织功能中的SSAT(通过转包
与J.Janne博士的团队达成协议(芬兰库奥皮奥);4)利用系统
在AIMS 1-3中开发,用于研究SSAT在确定抗肿瘤和
临床相关多胺拮抗剂的毒性反应;5)
通过杂交实验确定SSAT过度表达是否会导致
动物或多或少容易发生皮肤癌,这是一种
与目标5相关,他们建议检查肿瘤促进剂对
SSAT基因表达与蛋白激酶C的可能介导性作用
TPA和多胺类似物对SSAT的诱导作用。除了……之外
研究这种不寻常的酶反应的生物学意义,
拟议的研究旨在提供治疗洞察力和
临床前模型系统,用于促进正在进行的临床和
实验性抗癌靶向治疗的临床前研究进展
多胺。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CARL W PORTER其他文献
CARL W PORTER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CARL W PORTER', 18)}}的其他基金
Antiproliferative Potential of Polyamine Catabolism
多胺分解代谢的抗增殖潜力
- 批准号:
6870266 - 财政年份:1998
- 资助金额:
$ 28.65万 - 项目类别:
Antiproliferative Potential of Polyamine Catabolism
多胺分解代谢的抗增殖潜力
- 批准号:
6614750 - 财政年份:1998
- 资助金额:
$ 28.65万 - 项目类别:
Antiproliferative Potential of Polyamine Catabolism
多胺分解代谢的抗增殖潜力
- 批准号:
7031629 - 财政年份:1998
- 资助金额:
$ 28.65万 - 项目类别:
Antiproliferative Potential of Polyamine Catabolism
多胺分解代谢的抗增殖潜力
- 批准号:
7214077 - 财政年份:1998
- 资助金额:
$ 28.65万 - 项目类别:
Antiproliferative Potential of Polyamine Catabolism
多胺分解代谢的抗增殖潜力
- 批准号:
6730529 - 财政年份:1998
- 资助金额:
$ 28.65万 - 项目类别:
FACILITATING THE CLINICAL EVALUATION OF DENSPM
促进 DENSPM 的临床评估
- 批准号:
2458155 - 财政年份:1995
- 资助金额:
$ 28.65万 - 项目类别:
FACILITATING THE CLINICAL EVALUATION OF DENSPM
促进 DENSPM 的临床评估
- 批准号:
2109135 - 财政年份:1995
- 资助金额:
$ 28.65万 - 项目类别:
相似海外基金
The analysis of proteinuria caused by antineoplastics and the preventative effects with antihypertensive medications using the Japanese medical database
利用日本医学数据库分析抗肿瘤药物引起的蛋白尿及抗高血压药物的预防效果
- 批准号:
21K17258 - 财政年份:2021
- 资助金额:
$ 28.65万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Expediting Drug Development by Profiling Novel Antineoplastics by Mass Spectrometry-based Biomarker Profiling
通过基于质谱的生物标志物分析来分析新型抗肿瘤药物,加速药物开发
- 批准号:
499958-2016 - 财政年份:2016
- 资助金额:
$ 28.65万 - 项目类别:
Engage Grants Program
Combinatorial Peptidomimetics as Antineoplastics
作为抗肿瘤药的组合肽模拟物
- 批准号:
6623455 - 财政年份:2002
- 资助金额:
$ 28.65万 - 项目类别:
Combinatorial Peptidomimetics as Antineoplastics
作为抗肿瘤药的组合肽模拟物
- 批准号:
6465958 - 财政年份:2002
- 资助金额:
$ 28.65万 - 项目类别:
Novel Nanoparticle Delivery System for Antineoplastics
新型抗肿瘤纳米颗粒输送系统
- 批准号:
6483914 - 财政年份:2002
- 资助金额:
$ 28.65万 - 项目类别:
GLYCOLIPIDS AND CYTOTOXIC RESPONSE TO ANTINEOPLASTICS
糖脂和抗肿瘤药物的细胞毒性反应
- 批准号:
6124630 - 财政年份:1998
- 资助金额:
$ 28.65万 - 项目类别:
GLYCOLIPIDS AND CYTOTOXIC RESPONSE TO ANTINEOPLASTICS
糖脂和抗肿瘤药物的细胞毒性反应
- 批准号:
6329037 - 财政年份:1998
- 资助金额:
$ 28.65万 - 项目类别:
GLYCOLIPIDS AND CYTOTOXIC RESPONSE TO ANTINEOPLASTICS
糖脂和抗肿瘤药物的细胞毒性反应
- 批准号:
2747737 - 财政年份:1998
- 资助金额:
$ 28.65万 - 项目类别:
POLYMORPHIC METABOLISM OF ANTINEOPLASTICS IN CHILDREN
儿童抗肿瘤药物的多态性代谢
- 批准号:
3459680 - 财政年份:1990
- 资助金额:
$ 28.65万 - 项目类别:
POLYMORPHIC METABOLISM OF ANTINEOPLASTICS IN CHILDREN
儿童抗肿瘤药物的多态性代谢
- 批准号:
3459678 - 财政年份:1990
- 资助金额:
$ 28.65万 - 项目类别: